Abiopharma

🔍 Robinhood Markets, Inc. (Executive)

Company: Robinhood Ventures Fund I (RVI)

Report Date: 2026-08-13

Detailed Transactions and Holdings:

• Sold 9,757 shares of Common Shares of Beneficial Interest at $28.73 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 13,053,232.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 71 shares of Common Shares of Beneficial Interest at $29.13 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 13,053,161.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 5,482 shares of Common Shares of Beneficial Interest at $28.49 per share (Direct)
  Date: 2026-08-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 13,047,679.00 | transaction_form_type: 4 | Footnotes: F3, F2

Footnotes:

• F1: This is the weighted average sale price. Shares were sold in multiple transactions at prices from $28.135 to $29.075. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1).
• F2: Total shares held reflects the stock split that was effective immediately before the completion of the initial public offering, which resulted in each share outstanding as of March 5, 2026 being classified into 1.0239 shares of beneficial interest.
• F3: This is the weighted average sale price. Shares were sold in multiple transactions at prices from $28.27 to $28.977. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3).